Similar articles

• Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation.

  Niebler RA, Punzalan RC, Marchan M, Lankiewicz MW. Niebler RA, et al. Pediatr Crit Care Med. 2010 Jan;11(1):98-102. doi: 10.1097/PCC.0b013e3181b0620b. Pediatr Crit Care Med. 2010. PMID: 19561557
• Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation.

  Chalwin RP, Tiruvoipati R, Peek GJ. Chalwin RP, et al. Eur J Cardiothorac Surg. 2008 Sep;34(3):685-6. doi: 10.1016/j.ejcts.2008.05.022. Epub 2008 Jun 25. Eur J Cardiothorac Surg. 2008. PMID: 18579402
• Use of recombinant activated factor VII in children.

  Hammer GB, Williams GD. Hammer GB, et al. Paediatr Anaesth. 2007 Dec;17(12):1123-5. doi: 10.1111/j.1460-9592.2007.02344.x. Paediatr Anaesth. 2007. PMID: 17986029 No abstract available.
• Recombinant factor VIIa: a universal hemostatic agent?

  Lloyd JV, Joist JH. Lloyd JV, et al. Curr Hematol Rep. 2002 Sep;1(1):19-26. Curr Hematol Rep. 2002. PMID: 12901121 Review.
• Anticoagulation and coagulation management for ECMO.

  Oliver WC. Oliver WC. Semin Cardiothorac Vasc Anesth. 2009 Sep;13(3):154-75. doi: 10.1177/1089253209347384. Semin Cardiothorac Vasc Anesth. 2009. PMID: 19767408 Review.